Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01417429 · ClinicalTrials.gov registry record · Phase 1
Galantamine Effects on Nicotine Responses in Smokers
A Phase 1 study of Smoking and Tobacco Withdrawal, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01417429: Completed Phase 1 study of Smoking and Tobacco Withdrawal, sponsored by Yale University.
NCT01417429 is a Phase 1 study of Smoking and Tobacco Withdrawal that has completed, run by Yale University. The registered enrollment target is 12 participants, below the 455-participant average among 123 other Smoking trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01417429, a Phase 1 study of Smoking and Tobacco Withdrawal, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a 2-4 week double-blind, placebo-controlled study. Twenty four male and female smokers will first have two 4-day treatment periods, in which they will be randomized to galantamine (8 mg/day) or placebo. These treatment periods will be separated by a 3 to 14 day washout period. During the first 3-days of each treatment period, smokers will have daily clinic visits, where they will receive study medications and any adverse effects from study medications will be monitored. Starting at 10 p.m. on Day 1 of each treatment period, subjects will refrain from smoking for approximately 2.5 days, until the experimental session on Day 4. Compliance with non-smoking will be verified by CO levels \< 10 ppm. During the experimental sessions, subjects will receive saline or 1.0 mg/70 kg of nicotine intravenously in a random, double-blind manner. The sequence of nicotine treatments will be counterbalanced among subjects such that equal number of subjects will receive saline first or nicotine first. Following each saline and nicotine treatments, physiological, subjective and cognitive measurements will be obtained
Primary Outcome
Urine sample and blood samples anticipated for 24 male and females
Conditions Studied
Interventions
- DRUG Galantamine
- DRUG IV Nicotine
Study Locations (1)
Connecticut
- Department of Veterans Affairs - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
What the finished NCT01417429 record still lists
NCT01417429 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 455-participant average among 123 other Smoking trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Smoking appearing as the primary indexed condition, and to 2 interventions - of which Galantamine is the first listed.
NCT01417429 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT01417429 about?
NCT01417429 is a clinical study titled "Galantamine Effects on Nicotine Responses in Smokers". This will be a 2-4 week double-blind, placebo-controlled study. Twenty four male and female smokers will first have two 4-day treatment periods, in which they will be randomized to galantamine (8 mg/day) or placebo. These treatment periods will be separated by a 3 to 14 day washout period. During th...
What is the current status of trial NCT01417429?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-03. Estimated completion is 2011-03.
What conditions does trial NCT01417429 study?
This clinical trial studies the following conditions: Smoking, Tobacco Withdrawal.
What interventions are being tested in trial NCT01417429?
The interventions under investigation include: Galantamine (DRUG), IV Nicotine (DRUG).
Who is sponsoring clinical trial NCT01417429?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01417429 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01417429's enrollment target sits among peer trials
12 122nd of 123 higher than 2 of 123 other Smoking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Smoking Cessation for Depressed Smokers
ACTIVE NOT RECRUITING · Phase 1
-
Group Counseling for Smoking Cessation
COMPLETED · Phase 1
-
A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers
COMPLETED · Phase 1
-
Integrating Financial Coaching and Smoking Cessation Coaching
RECRUITING · Phase 3
-
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
RECRUITING
-
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia